Inhibition of human chorionic gonadotropin β-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells

Prostate

Volumn 53, Issue 3, 2002, Pages 200-210

  Devi, Gayathri R ^a   Oldenkamp, Jennifer R ^a   London, Carla A ^a   Iversen, Patrick L ^a  

^a AVI BIOPHARMA INC   (United States)

Author keywords

hCG; Antisense; c myc; Phosphorodiamidate morpholino oligomers; Prostate epithelial cells

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CHORIONIC GONADOTROPIN BETA SUBUNIT; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ARTICLE; CANCER GROWTH; CONTROLLED STUDY; HUMAN; HUMAN CELL; MITOGENESIS; ONCOGENE C MYC; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; BIOLOGICAL AVAILABILITY; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; MORPHOLINES; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHORUS COMPOUNDS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; RANDOM ALLOCATION; SPECIFIC PATHOGEN-FREE ORGANISMS; TUMOR CELLS, CULTURED;

EID: 0036842272     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10151     Document Type: Article

References (47)

1. Kirby RS, Christmas TJ, Brawer MK. Prostate Cancer. 2nd Ed. England: Mosby International Limited; 2001. 230 p.
2. Summerton J, Weller D. Morpholino antisense oligomers: Design, preparation and properties. Antisense Nucleic Acid Drug Dev 1997;7:187-195.
3. Ghosh C, Stein D, Weller D, Iversen PL. Evaluation of antisense mechanisms of action. Methods Enzymol 2000;313:135.
4. Iversen PL. PMO: favorable properties for sequence-specific inactivation. Curr Opin Mol Ther 2001;3:235-238.
5. Taylor MF, Weller DD, Kobzik L. Effect of TNF-alpha antisense on cytokine production by primary murine alveolar macrophages. Antisense Nucleic Acid Drug Dev 1998;8:199-205.
6. Giles RV, Spiller DG, Clark RE, Tidd DM. Antisense morpholino oligonucleotide analog induces missplicing of c-myc mRNA. Antisense Nucleic Acid Drug Dev 1999;9:213-220.
7. Hudziak RM, Summerton J, Weller DD, Iversen PL. Antiproliferative effects of steric blocking phosphorodiamidate morpholino antisense agents directed against c-myc. Antisense Nucleic Acid Drug Dev 2000;10:163-176.
8. Lacerra G, Sierakowska H, Carestia C, Fucharoen S, Summerton J, Weller D, Kole R. Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc Natl Acad Sci USA 2000;97:9591-9596.
9. Arora V, Knapp DC, Smith BL, Statdfield ML, Stein DA, Reddy MT, Weller DD, Iversen PL. c-myc antisense rat liver regeneration and indicates role for c-myc in regulating cytochrome P-450 3A activity. J Pharmacol Exp Ther 2000;292:921-928.
10. Nasevicius A, Ekker SC. Effective targeted gene knockout in zebrafish. Nat Genet 2000;26:216-220.
11. Qin G, Taylor M, Ning YY, Iversen P, Kobzik L. In vivo evaluation of a morpholine oligomer directed against TNF-α. Antisense Nucleic Acid Drug Dev 2000;10:11-16.
12. Broder LE, Weintraub BD, Rosen SW, Cohen MH, Tejada F. Placental proteins and their subunits as tumor markers in prostatic carcinoma. Cancer 1977;40:211-216.
13. Gregory JJ, Finlay JL. Alpha-fetoprotein and beta-human chorionic gonadotropin: Their clinical significance as tumor markers. Drugs 1999;57:463-467.
14. Pierce JG, Parsons TF. Glycoprotein hormones: Structure and function. Annu Rev Biochem 1981;50:465-495.
15. Sheaff MT, Martin JE, Badenoch DF, Baithun SI. βhCG as a prognostic marker in adenocarcinoma of the prostate. J Clin Pathol 1996;49:329-332.
16. Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 1998, 2:295-302.
17. Fukutani K, Libby JM, Panko WB, Scardino PT. Human chorionic gonadotropin detected in urinary concentrates from patients with malignant tumors of the testis, prostate, bladder, ureter and kidney. J Urol 1983;129:74-77.
18. Lin T, Baidsdell J, Barbour KW, Thompson EA. Transient activation of c-myc protooncogene expression in Leydig cells by human chorionic gonadotropin. Biochem Biophys Res Commun 1988;157:121-126.
19. Czerwiec FS, Melner MH, Puett D. Transiently elevated levels of c-fos and c-myc oncogene messenger ribonucleic acids in cultured murine Leydig tumor cells after addition of human chorionic gonadotropin. Mol Endocrinol 1989;3:105-109.
20. Schultz R, Kononen J, Pelto-Huikko M. Induction of immediate early gene mRNAs and proteins by hCG in interstitial cells of rat testis. J Endocrinol 1995;144:417-424.
21. Nupponen NN, Visakorpi T. Molecular cytogenetics of prostate cancer. Microsc Res Tech 2000;51:456-463.
22. Zhang X, Lee C, Ng P, Rubin M, Shabsigh A, Buttyan R. Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein. Prostate 2000;43:278-285.
23. Ghosh CM, Iversen PL. Intracellular delivery strategies for antisense phosphorodiamidate morpholino oligomers. Antisense Nucleic Acid Drug Dev 2000;10:263-274.
24. Arora A, Knapp DC, Reddy MT, Weller DD, Iversen PL. Bioavailability and efficacy of antisense Morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats. J Pharm Sci 2002;91:1009-1018.
25. Morcos P. Achieving efficient delivery of Morpholino oligos in cultured cells. Genesis 2001;30:94-102.
26. Stein DA, Skilling DE, Iversen PL, Smith AW. Inhibition of vesivirus infections in mammalian tissue culture with antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev 2001; 5:317-325.
27. Kaneko K, Satoh K, Masamune A, Satoh A, Shimosegawa T. Expression of ROCK-1 in human pancreatic cancer: Its down-regulation by morpholino oligo antisense can reduce the migration of pancreatic cancer cells in vitro. Pancreas 2002;3:251-257.
28. Arora V, Cate ML, Ghosh C, Iversen PL. Phosphorodiamidate morpholino oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism. Drug Metab Dispos 2002;300:757-762.
29. Calabretta B. Inhibition of protooncogene expression by antisense oligodeoxynucleotides: Biological and therapeutic implications. Cancer Res 1991;51:4505-4510.
30. Pawlak W, Zolnierek J, Sarosiek T, Szczylik C. Antisense therapy in cancer. Cancer Treat Rev 2000;26:333-350.
31. Qian J, Hirasawa K, Bostwick DG, Bergstralh EJ, Slezak JM, Anderl KL, Borell TJ, Lieber MM, Jenkins RB. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod Pathol 2002;1:35-44.
32. Grad JM, Dai JL, Wu S, Burnstein KL. Multiple androgen response elements and a myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA. Mol Endocrinol 1999;13: 1896-1911.
33. Kaltz-Wittmer C, Klenk U, Glaessgen A, Aust DE, Diebold J, Lohrs U, Baretton GB. Fish analysis of gene aberrations in advanced prostatic carcinomas before and after androgen deprivation therapy. Lab Invest 2000;80:1455-1464.
34. Kokontis J, Takakura K, Hay N, Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 1994;54: 1566-1573.
35. Balaji KC, Koul H, Mitra S, Maramag C, Reddy P, Menon M, Malhotra RK, Laxmanan S. Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: A novel therapy in prostate cancer. J Urol 1997;50:1007-1015.
36. Steiner MS, Anthony CT, Lu Y, Holt JTL. Antisense c-myc retroviral vector suppresses established human prostate cancer. Hum Gene Ther 1998;9:747-755.
37. Rijnders AWM, Van Der Korput JAGM, Van Steenbrugge GJ, Romijn JC, Trapman J. Expression of cellular oncogenes in human prostatic carcinoma cell lines. Biochem Biophys Res Commun 1985;132:548-554.
38. Fleming WH, Hamel A, MacDonald R, Ramsey E, Pettigrew NM, Johnston B, Dodd JG, Matusik RJ. Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res 1986;46:1535-1538.
39. Bookstein R, Shew JY, Chen PL, Scully P, Lee WH. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated Rb gene. Science 1990;247:712-715.
40. Zhao X, Day ML. Rb activation and repression of c-myc transcription precede apoptosis of human prostate epithelial cells. J Urol 2001;57:860-865.
41. Rubenstein M, Guinan P. A review of various antisense oligonucleotide therapeutic approaches for prostate cancer. Prostate 2000;2:179-188.
42. Acevedo HF, Hartsock RJ. Metastatic phenotype correlates with high expression of associated complete β-human chorionic gonadotropin in vivo. Cancer 1996;78:2388-2399.
43. Bellet D, Lazar V, Bieche I, Paradis V, Giovangrandi Y, Paterlini P, Lidereau R, Bedossa P, Bidart JM, Vidaud M. Malignant transformation of nontrophoblastic cells is associated with the expression of chorionic gonadotropin beta genes normally transcribed in trophoblastic cells. Cancer Res 1997;57: 516-523.
44. Daaka Y, Luttrell LM, Ahn S, Della Rocca GJ, Ferguson SG, Caron MG, Lefkowitz RJ. Essential role for g protein-coupled receptor endocytosis in the activation of mitogen-activated protein kinase. J Biol Chem 1998;273:685-688.
45. Kipshidze N, Keane E, Stein D, Chawla P, Skrinska V, Shankar LR, Khanna A, Komorowski R, Haudenschild C, Iversen P, Leon MB, Keelan MH, Moses J. Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Cathet Cardiovasc Interv 2001;54:247-256.
46. Ricker JL, Mata JE, Iversen PL, Gattone VH. c-myc antisense oligomer treatment ameliorates murine infantile polycystic kidney disease. Kidney Int 2002;61(Suppl 1):125-131.
47. Devi GR. Prostate cancer: Status of current treatments and emerging antisense-based therapies. Curr Opin Mol Ther 2002;4: 138-148.